» Articles » PMID: 24011086

Activation of NF-κB by the RANKL/RANK System Up-regulates Snail and Twist Expressions and Induces Epithelial-to-mesenchymal Transition in Mammary Tumor Cell Lines

Abstract

Background: Increased motility and invasiveness of cancer cells are reminiscent of the epithelial-mesenchymal transition (EMT), which occurs during cancer progression and metastasis. Recent studies have indicated the expression of receptor activator of nuclear factor-κB (RANK) in various solid tumors, including breast cancer. Although activation of the RANK ligand (RANKL)/RANK system promotes cell migration, metastasis, and anchorage-independent growth of tumor-initiating cells, it remains to be investigated if RANKL induces EMT in breast cancer cells. In this study, we investigated whether RANKL induces EMT in normal breast mammary epithelial cells and breast cancer cells, and the mechanism underlying such induction.

Methods: Expression levels of vimentin, N-cadherin, E-cadherin, Snail, Slug, and Twist were examined by real-time polymerase chain reaction. Cell migration and invasion were assessed using Boyden chamber and invasion assays, respectively. The effects of RANKL on signal transduction molecules were determined by western blot analyses.

Results: We found that stimulation by RANKL altered the cell morphology to the mesenchymal phenotype in normal breast epithelial and breast cancer cells. In addition, RANKL increased the expression levels of vimentin, N-cadherin, Snail, and Twist and decreased the expression of E-cadherin. We also found that RANKL activated nuclear factor-κB (NF-κB), but not extracellular signal-regulated kinase 1/2, Akt, mammalian target of rapamycin, c-Jun N-terminal kinase, and signal transducer and activator of transcription 3. Moreover, dimethyl fumarate, a NF-κB inhibitor, inhibited RANKL-induced EMT, cell migration, and invasion, and upregulated the expressions of Snail, Twist, vimentin, and N-cadherin.

Conclusions: The results indicate that RANKL induces EMT by activating the NF-κB pathway and enhancing Snail and Twist expression. These findings suggest that the RANKL/RANK system promotes tumor cell migration, invasion, and metastasis via the induction of EMT.

Citing Articles

Targeting epithelial-mesenchymal transition signaling pathways with Dietary Phytocompounds and repurposed drug combinations for overcoming drug resistance in various cancers.

Sravani A, Thomas J Heliyon. 2025; 11(3):e41964.

PMID: 39959483 PMC: 11830326. DOI: 10.1016/j.heliyon.2025.e41964.


NF-κB pathway and angiogenesis: insights into colorectal cancer development and therapeutic targets.

Bahrami A, Khalaji A, Najafi M, Sadati S, Raisi A, Abolhassani A Eur J Med Res. 2024; 29(1):610.

PMID: 39702532 PMC: 11658081. DOI: 10.1186/s40001-024-02168-w.


Oxaliplatin and 5-fluorouracil promote epithelial-mesenchymal transition via activation of KRAS/ERK/NF-κB pathway in KRAS-mutated colon cancer cells.

Hoshida T, Tsubaki M, Takeda T, Asano R, Choi I, Takimoto K Mol Cell Biochem. 2024; .

PMID: 39586908 DOI: 10.1007/s11010-024-05157-z.


RANK-RANKL-OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives.

Monti F, Perazza F, Leoni L, Stefanini B, Ferri S, Tovoli F Int J Mol Sci. 2024; 25(17).

PMID: 39273141 PMC: 11395242. DOI: 10.3390/ijms25179193.


Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer.

Javed S, Skolariki A, Zameer M, Lord S Br J Cancer. 2024; 131(11):1724-1736.

PMID: 39251829 PMC: 11589622. DOI: 10.1038/s41416-024-02833-1.


References
1.
Armstrong A, Tometsko M, Glaccum M, Sutherland C, Cosman D, Dougall W . A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem. 2002; 277(46):44347-56. DOI: 10.1074/jbc.M202009200. View

2.
Li C, Xia W, Huo L, Lim S, Wu Y, Hsu J . Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1. Cancer Res. 2012; 72(5):1290-300. PMC: 3350107. DOI: 10.1158/0008-5472.CAN-11-3123. View

3.
Glantschnig H, Fisher J, Wesolowski G, Rodan G, Reszka A . M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ. 2003; 10(10):1165-77. DOI: 10.1038/sj.cdd.4401285. View

4.
Mu Y, Gudey S, Landstrom M . Non-Smad signaling pathways. Cell Tissue Res. 2011; 347(1):11-20. DOI: 10.1007/s00441-011-1201-y. View

5.
Canon J, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik P . Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis. 2007; 25(2):119-29. DOI: 10.1007/s10585-007-9127-1. View